Shobhit Seth

Shobhit Seth is a freelance financial writer, derivatives trader and consultant specializing in derivatives pricing and quantitative research. His career spans over 14 years as a Product Manager (Derivatives, Financial Data & Risk Management) at leading financial services companies across the UK, Europe, US and India. He has written extensively on topics pertaining to Derivatives Pricing, Derivatives Combinations & Structures, and Derivatives Trading Strategies. A lot of his work is available at www.FuturesOptionsETC.com, a site on Derivatives Trading which Shobhit owns and maintains. Shobhit also has expertise in index based products and ETFs, and he conducts training sessions on derivatives and related financial topics.

Shobhit has a Master’s degree in Financial Management (Specialization in Derivatives & Quantitative Research) from the Netherlands and a Bachelor of Technology degree (Electronics & Communications Engineering) from India.

  • Showing 1-15 of 1,033 items
  • 1
  • 2
  • 3
  • ...
  • 69
  • >>
  1. Stocks

    Jose Cuervo IPO First Mexican Offering Since Trump Took Office

    After delaying its IPO twice during the last year, Jose Cuervo, the world's biggest tequila distiller, went public earlier ...
  2. Stocks

    Momenta 4Q Net 60 Cents a Share (MNTA)

    Momenta’s 4Q earnings came in at a healthy 60 cents per share, or $41.5 million.
  3. Stocks

    Albany Molecular Research 4Q Misses Street (AMRI)

    Albany Molecular Research's 4Q earnings and revenues fell below Wall Street estimates.
  4. Stocks

    BioTime Reports $56M Non-Cash Gain (BTX,OCX)

    BioTime will post a non-cash gain on the deconsolidation of its OncoCyte unit.
  5. Stocks

    Amgen Gets EU Nod for Monthly Repatha Dose (AMGN)

    Amgen expects to launch the monthly-dose version of the cholesterol drug in the EU later this year.
  6. Stocks

    VBL's Thyroid Cancer Drug Clears Phase 2 (VBLT)

    The multiple-indication drug VB-111 reported positive data for treating thyroid cancer.
  7. Stocks

    Exactech Posts Q4 Loss of 82 Cents a Share (EXAC)

    Exactech reported a 4Q loss of 82 cents a share compared to earnings of 29 cents last year.
  8. Stocks

    Cidara Yeast Infection Gel Fails Phase 2 (CDTX)

    Cidara discontinued development of its anti-fungal topical after a Phase 2 trial failure.
  9. Stocks

    Medtronic 3Q Earnings Beat Street (MDT)

    Medical device maker Medtronic reported better-than-expected 3Q earnings of $1.12 a share.
  10. Stocks

    FDA Rejects Amphastar Opioid Overdose Drug (AMPH)

    FDA has issued a CRL for Amphastar’s nasal spray version of opioid-overdose therapy Naloxone Hydrochloride
  11. Stocks

    Trevena Plunges 34% On Painkiller Results (TRVN)

    Trevena’s painkiller oliceridine beat a placebo, but faltered against morphine in a clinical study.
  12. Stocks

    Philips Monitoring System Gets FDA Clearance (PHG)

    Philips got FDA clearance for an in-patient continuous monitoring system.
  13. Stocks

    Sarepta Sells Priority Review Voucher for $125M (SRPT)

    Sarepta sold its Priority Review Voucher for $125 million to Gilead.
  14. Stocks

    BrainStorm Seeks ALS Drug Nod In Canada (BCLI)

    BrainStorm is seeking early approval in Canada for its ALS drug.
  15. Stocks

    Roche Lung Cancer Drug Alecensa Gets EU Nod (RHHBY)

    Roche’s Alecensa adds the large EU market for non-small cell lung cancer treatment.
  • Showing 1-15 of 1,033 items
  • 1
  • 2
  • 3
  • ...
  • 69
  • >>